Hellow guys, Welcome to my website, and you are watching The latest treatment options for BRCA-mutated breast cancer. and this vIdeo is uploaded by VJOncology at 2021-03-16T10:11:21-07:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | The latest treatment options for BRCA-mutated breast cancer |
| Video Uploader | Video From VJOncology |
| Upload Date | This Video Uploaded At 16-03-2021 17:11:21 |
| Video Discription | Judy Garber, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, shares an overview of the latest treatment options for BCRA1/2-mutated breast cancer. Recent evidence from the INFORM trial (NCT01670500) has shown a lack of benefit of platinum-based chemotherapy over doxorubicin-cyclophosphamide in BRCA carriers with HER2-negative breast cancer. Aside from chemotherapy, the use of PARP inhibitors has greatly expanded in patients with BRCA-mutated breast cancer in recent years, in both the neoadjuvant and advanced disease treatment settings. Data from many trials have demonstrated benefits. These agents are now under examination in novel combinations and beyond the BRCA setting, such as the TBCRC 048 olaparib expanded study (NCT03344965) of olaparib in patients with an acquired DNA repair mutation or a germline breast cancer susceptibility gene other than BRCA1/2. This interview took place during the 17th St. Gallen International Breast Cancer Conference. |
| Category | Education |
| Tags | Speaker: Judy Garber | Institution: Dana-Farber Cancer Institute | Event: BCC 2021 | Format: Interview | Subject: Breast Cancer | Field: Treatment | Trial: TBCRC 048 | Trial: INFORM | Medicines: Olaparib | Medicines: Doxorubicin | Medicines: Cyclophosphamide | Medicines: Cisplatin | TNBC | HR+ | HER2+ | BRCA1 | BRCA2 | PARP inhibitors | chemotherapy | NCT03344965 | NCT01670500 | Field: Trial Updates |
